Genetic modification of the heart: Exploring necessity and sufficiency in the past 10 years

Journal of Molecular and Cellular Cardiology

Volumn 36, Issue 5, 2004, Pages 643-652

  Robbins, Jeffrey ^a  

^a CINCINNATI CHILDREN'S HOSPITAL MEDICAL CENTER   (United States)

Author keywords

Gene; Gene ablation; Heart; Mouse genetics; Transgenesis

Indexed keywords

ANTIGESTAGEN; MIFEPRISTONE; PROTEIN; RECOMBINASE; TAMOXIFEN;

ALLELE; CARDIOVASCULAR DISEASE; CHROMATIN; DNA MODIFICATION; DNA SEQUENCE; GENE EXPRESSION; GENE LIBRARY; GENE MUTATION; GENE TARGETING; GENETIC ENGINEERING; HEART; HETEROZYGOTE; HOMOZYGOTE; MAJOR HISTOCOMPATIBILITY COMPLEX; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN FUNCTION; REVIEW; SACCHAROMYCES CEREVISIAE; TECHNOLOGY; TRANSGENIC MOUSE; TRANSGENICS;

ANIMALS; GENE TARGETING; GENETIC TECHNIQUES; HEART; HUMANS; MYOCARDIUM; TRANSGENES;

ANIMALIA; MURINAE;

EID: 2342631203     PISSN: 00222828     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.yjmcc.2004.02.012     Document Type: Review

References (81)

1. Zong Q., Schummer M., Hood L., Morris D.R. Messenger RNA translation state: the second dimension of high-throughput expression screening. Proc Natl Acad Sci USA. 96:1999;10632-10636
2. Wilkie G.S., Dickson K.S., Gray N.K. Regulation of mRNA translation by 5′- and 3′-UTR-binding factors. Trends Biochem Sci. 28:2003;182-188
3. Figueredo V.M., Camacho S.A. Basic mechanisms of myocardial dysfunction: cellular pathophysiology of heart failure. Curr Opin Cardiol. 10:1995;246-252
4. Blaufarb I.S., Sonnenblick E.H. The renin-angiotensin system in left ventricular remodeling. Am J Cardiol. 77:1996;8C-16C
5. Meggs L.G., Huang H., Tillotson J., Capasso J.M., Anversa P. Re-expression of alpha skeletal actin and regulation of alpha 1 adrenoceptor signalling in DOCA-salt hypertension in rats. Cardiovasc Res. 26:1992;878-885
6. Barany M. ATPase activity of myosin correlated with speed of muscle shortening. J Gen Physiol 1967;50(6):Suppl. 197-218
7. Morano M., Zacharzowski U., Maier M., Lange P.E., Alexi-Meskishvili V., Haase H., et al. Regulation of human heart contractility by essential myosin light chain isoforms. J Clin Invest. 98:1996;467-473
8. Boluyt M.O., O'Neill L., Meredith A.L., Bing O.H., Brooks W.W., Conrad C.H., et al. Alterations in cardiac gene expression during the transition from stable hypertrophy to heart failure. Marked upregulation of genes encoding extracellular matrix components. Circ Res. 75:1994;23-32
9. Braz J.C., Bueno O.F., Liang Q., Wilkins B.J., Dai Y.S., Parsons S., et al. Targeted inhibition of p38 MAPK promotes hypertrophic cardiomyopathy through upregulation of calcineurin-NFAT signaling. J Clin Invest. 111:2003;1475-1486
10. Dorn G.W. II, Molkentin J.D. Manipulating cardiac contractility in heart failure: data from mice and men. Circulation. 109:2004;150-158
11. Palmiter R.D., Brinster R.L. Transgenic mice. Cell. 41:1985;343-345
12. Bonifer C., Hecht A., Saueressig H., Winter D.M., Sippel A.E. Dynamic chromatin: the regulatory domain organization of eukaryotic gene loci. J Cell Biochem. 47:1991;99-108
13. Allen N.D., Cran D.G., Barton S.C., Hettle S., Reik W., Surani M.A. Transgenes as probes for active chromosomal domains in mouse development. Nature. 333:1988;852-855
14. Grosveld F., van Assendelft G.B., Greaves D.R., Kollias G. Position-independent, high-level expression of the human beta-globin gene in transgenic mice. Cell. 51:1987;975-985
15. Costantini F., Radice G., Lee J.L., Chada K.K., Perry W., Son H.J. Insertional mutations in transgenic mice. Prog Nucleic Acid Res Mol Biol. 36:1989;159-169
16. Krulewski T.F., Neumann P.E., Gordon J.W. Insertional mutation in a transgenic mouse allelic with Purkinje cell degeneration. Proc Natl Acad Sci USA. 86:1989;3709-3712
17. Singh G., Supp D.M., Schreiner C., McNeish J., Merker H.J., Copeland N.G., et al. Legless insertional mutation: morphological, molecular, and genetic characterization. Genes Dev. 5:1991;2245-2255
18. Supp D.M., Witte D.P., Potter S.S., Brueckner M. Mutation of an axonemal dynein affects left-right asymmetry in inversus viscerum mice. Nature. 389:1997;963-966
19. Supp D.M., Brueckner M., Kuehn M.R., Witte D.P., Lowe L.A., McGrath J., et al. Targeted deletion of the ATP binding domain of left-right dynein confirms its role in specifying development of left-right asymmetries. Development. 126:1999;5495-5504
20. Babinet C., Morello D., Renard J.P. Transgenic mice. Genome. 31:1989;938-949
21. Field L.J. Transgenic mice in cardiovascular research. Annu Rev Physiol. 55:1993;97-114
22. Robbins J., Palermo J., Rindt H. In vivo definition of a cardiac specific promoter and its potential utility in remodeling the heart. Ann NY Acad Sci. 752:1995;492-505
23. Knotts S., Rindt H., Neumann J., Robbins J. In vivo regulation of the mouse beta myosin heavy chain gene. J Biol Chem. 269:1994;31275-31282
24. Subramaniam A., Jones W.K., Gulick J., Wert S., Neumann J., Robbins J. Tissue-specific regulation of the alpha-myosin heavy chain gene promoter in transgenic mice. J Biol Chem. 266:1991;24613-24620
25. Hunter J.J., Zhu H., Lee K.J., Kubalak S., Chien K.R. Targeting gene expression to specific cardiovascular cell types in transgenic mice. Hypertension. 22:1993;608-617
26. Hunter J.J., Tanaka N., Rockman H.A., Ross J. Jr, Chien K.R. Ventricular expression of a MLC-2v-ras fusion gene induces cardiac hypertrophy and selective diastolic dysfunction in transgenic mice. J Biol Chem. 270:1995;23173-23178
27. Huang X., Pi Y., Lee K.J., Henkel A.S., Gregg R.G., Powers P.A., et al. Cardiac troponin I gene knockout: a mouse model of myocardial troponin I deficiency. Circ Res. 84:1999;1-8
28. Jones W.K., Grupp I.L., Doetschman T., Grupp G., Osinska H., Hewett T.E., et al. Ablation of the murine alpha myosin heavy chain gene leads to dosage effects and functional deficits in the heart. J Clin Invest. 98:1996;1906-1917
29. Buttrick P.M., Kaplan M.L., Kitsis R.N., Leinwand L.A. Distinct behavior of cardiac myosin heavy chain gene constructs in vivo. Discordance with in vitro results. Circ Res. 72:1993;1211-1217
30. Buttrick P.M., Kass A., Kitsis R.N., Kaplan M.L., Leinwand L.A. Behavior of genes directly injected into the rat heart in vivo. Circ Res. 70:1992;193-198
31. Knotts S., Rindt H., Robbins J. Position independent expression and developmental regulation is directed by the beta myosin heavy chain gene's 5′ upstream region in transgenic mice. Nucleic Acid Res. 23:1995;3301-3309
32. Robbins J. Remodeling the cardiac sarcomere using transgenesis. Annu Rev Physiol. 62:2000;261-287
33. Sanbe A., Gulick J., Hanks M.C., Liang Q., Osinska H., Robbins J. Reengineering inducible cardiac-specific transgenesis with an attenuated myosin heavy chain promoter. Circ Res. 92:2003;609-616
34. Soonpaa M.H., Field L.J. Survey of studies examining mammalian cardiomyocyte DNA synthesis. Circ Res. 83:1998;15-26
35. Gulick J., Hewett T.E., Klevitsky R., Buck S.H., Moss R.L., Robbins J. Transgenic remodeling of the regulatory myosin light chains in the mammalian heart. Circ Res. 80:1997;655-664
36. Mochly-Rosen D., Wu G., Hahn H., Osinska H., Liron T., Lorenz J.N., et al. Cardiotrophic effects of protein kinase C epsilon: analysis by in vivo modulation of PKCepsilon translocation. Circ Res. 86:2000;1173-1179
37. De Windt L.J., Lim H.W., Bueno O.F., Liang Q., Delling U., Braz J.C., et al. Targeted inhibition of calcineurin attenuates cardiac hypertrophy in vivo. Proc Natl Acad Sci USA. 98:2001;3322-3327
38. Ng W.A., Grupp I.L., Subramaniam A., Robbins J. Cardiac myosin heavy chain mRNA expression and myocardial function in the mouse heart. Circ Res. 68:1991;1742-1750
39. Dorn G.W. II, Robbins J., Ball N., Walsh R.A. Myosin heavy chain regulation and myocyte contractile depression after LV hypertrophy in aortic-banded mice. Am J Physiol. 267:1994;H400-H405
40. Mansuy I.M., Winder D.G., Moallem T.M., Osman M., Mayford M., Hawkins R.D., et al. Inducible and reversible gene expression with the rtTA system for the study of memory. Neuron. 21:1998;257-265
41. Gossen M., Bonin A.L., Freundlieb S., Bujard H. Inducible gene expression systems for higher eukaryotic cells. Curr Opin Biotechnol. 5:1994;516-520
42. Bujard H. Controlling genes with tetracyclines. J Gene Med. 1:1999;372-374
43. Freundlieb S., Baron U., Bonin A.L., Gossen M., Bujard H. Use of tetracycline-controlled gene expression systems to study mammalian cell cycle. Method Enzymol. 283:1997;159-173
44. Freundlieb S., Schirra-Muller C., Bujard H. A tetracycline controlled activation/repression system with increased potential for gene transfer into mammalian cells. J Gene Med. 1:1999;4-12
45. Russell L.K., Mansfield C.M., Lehman J.J., Kovacs A., Courtois M., Saffitz J.E., et al. Cardiac-specific induction of the transcriptional coactivator peroxisome proliferator-activated receptor {gamma} coactivator-1(alpha) promotes mitochondrial biogenesis and reversible cardiomyopathy in a developmental stage-dependent manner. Circ Res. 2004
46. Chien K.R. To Cre or not to Cre: the next generation of mouse models of human cardiac diseases. Circ Res. 88:2001;546-549
47. Huang W.Y., Aramburu J., Douglas P.S., Izumo S. Transgenic expression of green fluorescence protein can cause dilated cardiomyopathy. Nat Med. 6:2000;482-483
48. James J., Osinska H., Hewett T.E., Kimball T., Klevitsky R., Witt S., et al. Transgenic over-expression of a motor protein at high levels results in severe cardiac pathology. Transgenic Res. 8:1999;9-22
49. Kornberg R.D., Lorch Y. Twenty-five years of the nucleosome, fundamental particle of the eukaryote chromosome. Cell. 98:1999;285-294
50. Kornberg R.D., Lorch Y. Chromatin and transcription: where do we go from here. Curr Opin Genet Dev. 12:2002;249-251
51. Rindt H., Subramaniam A., Robbins J. An in vivo analysis of transcriptional elements in the mouse alpha-myosin heavy chain gene promoter. Transgenic Res. 4:1995;397-405
52. Hahn H.S., Yussman M.G., Toyokawa T., Marreez Y., Barrett T.J., Hilty K.C., et al. Ischemic protection and myofibrillar cardiomyopathy: dose-dependent effects of in vivo deltaPKC inhibition. Circ Res. 91:2002;741-748
53. van der Weyden L., Adams D.J., Bradley A. Tools for targeted manipulation of the mouse genome. Physiol Genomics. 11:2002;133-164
54. Doetschman T.C. Gene targeting in embryonic stem cells. Biotechnology. 16:1991;89-101
55. Smithies O., Gregg R.G., Boggs S.S., Koralewski M.A., Kucherlapati R.S. Insertion of DNA sequences into the human chromosomal beta-globin locus by homologous recombination. Nature. 317:1985;230-234
56. Capecchi M.R. Altering the genome by homologous recombination. Science. 244:1989;1288-1292
57. Bronson S.K., Plaehn E.G., Kluckman K.D., Hagaman J.R., Maeda N., Smithies O. Single-copy transgenic mice with chosen-site integration. Proc Natl Acad Sci USA. 93:1996;9067-9072
58. Hasty P., Ramirez-Solis R., Krumlauf R., Bradley A. Introduction of a subtle mutation into the Hox-2.6 locus in embryonic stem cells. Nature. 350:1991;243-246
59. Valancius V., Smithies O. Testing an "in-out" targeting procedure for making subtle genomic modifications in mouse embryonic stem cells. Mol Cell Biol. 11:1991;1402-1408
60. Lewis J., Yang B., Detloff P., Smithies O. Gene modification via "plug and socket" gene targeting. J Clin Invest. 97:1996;3-5
61. Askew G.R., Doetschman T., Lingrel J.B. Site-directed point mutations in embryonic stem cells: a gene-targeting tag-and-exchange strategy. Mol Cell Biol. 13:1993;4115-4124
62. Geisterfer-Lowrance A.A., Christe M., Conner D.A., Ingwall J.S., Schoen F.J., Seidman C.E., et al. A mouse model of familial hypertrophic cardiomyopathy. Science. 272:1996;731-734
63. Marth J.D. Recent advances in gene mutagenesis by site-directed recombination. J Clin Invest. 97:1996;1999-2002
64. Rajewsky K., Gu H., Kuhn R., Betz U.A., Muller W., Roes J., et al. Conditional gene targeting. J Clin Invest. 98:1996;600-603
65. Agah R., Frenkel P.A., French B.A., Michael L.H., Overbeek P.A., Schneider M.D. Gene recombination in postmitotic cells. Targeted expression of Cre recombinase provokes cardiac-restricted, site-specific rearrangement in adult ventricular muscle in vivo. J Clin Invest. 100:1997;169-179
66. Chen J., Kubalak S.W., Chien K.R. Ventricular muscle-restricted targeting of the RXRalpha gene reveals a non-cell-autonomous requirement in cardiac chamber morphogenesis. Development. 125:1998;1943-1949
67. Kwan K.M. Conditional alleles in mice: practical considerations for tissue-specific knockouts. Genesis. 32:2002;49-62
68. Sohal D.S., Nghiem M., Crackower M.A., Witt S.A., Kimball T.R., Tymitz K.M., et al. Temporally regulated and tissue-specific gene manipulations in the adult and embryonic heart using a tamoxifen-inducible Cre protein. Circ Res. 89:2001;20-25
69. Williams R.W., Flaherty L., Threadgill D.W. The math of making mutant mice. Genes Brain Behav. 2:2003;191-200
70. Hamada H. Random isolation of gene activator elements from the human genome. Mol Cell Biol. 6:1986;4185-4194
71. Stanford W.L., Cohn J.B., Cordes S.P. Gene-trap mutagenesis: past, present and beyond. Nat Rev Genet. 2:2001;756-768
72. von Melchner H., Ruley H.E. Identification of cellular promoters by using a retrovirus promoter trap. J Virol. 63:1989;3227-3233
73. Friedrich G., Soriano P. Promoter traps in embryonic stem cells: a genetic screen to identify and mutate developmental genes in mice. Genes Dev. 5:1991;1513-1523
74. Joyner A.L. Gene targeting and gene trap screens using embryonic stem cells: new approaches to mammalian development. Bioessays. 13:1991;649-656
75. Zhang W., Behringer R.R., Olson E.N. Inactivation of the myogenic bHLH gene MRF4 results in up-regulation of myogenin and rib anomalies. Genes Dev. 9:1995;1388-1399
76. Patapoutian A., Yoon J.K., Miner J.H., Wang S., Stark K., Wold B. Disruption of the mouse MRF4 gene identifies multiple waves of myogenesis in the myotome. Development. 121:1995;3347-3358
77. Braun T., Arnold H.H. Inactivation of Myf-6 and Myf-5 genes in mice leads to alterations in skeletal muscle development. EMBO J. 14:1995;1176-1186
78. Olson E.N., Arnold H.H., Rigby P.W., Wold B.J. Know your neighbors: three phenotypes in null mutants of the myogenic bHLH gene MRF4. Cell. 85:1996;1-4
79. Voorhoeve P.M., Agami R. Knockdown stands up. Trends Biotechnol. 21:2003;2-4
80. Shi Y. Mammalian RNAi for the masses. Trends Genet. 19:2003;9-12
81. van der Giessen K., Di-Marco S., Clair E., Gallouzi I.E. RNAi-mediated HuR depletion leads to the inhibition of muscle cell differentiation. J Biol Chem. 278:2003;47119-47128